Radiofrequency renal denervation confers sustained BP reduct
The researchers randomly assigned 80 patients (mean age, 53 years; 84% men) to receive radiofrequency renal denervation or a sham procedure. At 36 months, the number of medications taken was similar between the groups (renal denervation, 3; sham, 3.1; P = .76) and the medication burden, based on number of medications, class and dose, was numerically higher in the sham group (7.6 vs. 10.3; P = .26), according to the researchers.

The renal denervation group had greater lowering of 24-ambulatory systolic BP at 36 months compared with the sham group (–18.7 mm Hg vs. –8.6 mm Hg; P = .004), Mahfoud and colleagues found. The renal denervation group also had significantly lower systolic BP in the morning, during the daytime, during nighttime and in the office at 36 months compared with the sham group, according to the researchers. The percentage of patients with 24-hour systolic BP less than 140 mm Hg at 36 months was 83.3% in the renal denervation group and 43.8% in the sham group (P = .002), Mahfoud said during a presentation.

Radiofrequency renal denervation compared to sham control demonstrated clinically meaningful and statistically significant BP reductions independent of concomitant antihypertensive medications out to 36 months, without safety issues. Given the long-term safety and efficacy, renal denervation provides an attractive adjunctive treatment modality in the management of hypertension.